Why Your Appetite May Return on Wegovy — and What to Do About It

What STEP 1 trial data tells us about appetite and how it changes over time

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults on semaglutide 2.4mg for 68 weeks alongside lifestyle intervention. Average body-weight reduction was around 15%, and appetite suppression was a consistent driver of that result. But trial data also shows that the effect was not static. Hunger scores were most dramatically reduced in the early weeks of dose escalation and tended to stabilise, rather than intensify, as patients reached maintenance dose. That stabilisation is sometimes experienced subjectively as appetite "coming back", even though semaglutide is still active.

There is a common misconception worth setting aside here: that a returning sense of hunger means the medicine is failing. It rarely does. Weight loss can continue at a meaningful rate even when appetite is no longer as forcefully blunted as it was in week two. The drug's mechanism (slowing gastric emptying, acting on satiety signals in the brain, reducing reward-driven eating) does not switch off; it simply becomes less conspicuous as the body adjusts. Patients who interpret this as treatment failure sometimes reduce their food intake unnecessarily, which can cause nutrient deficiencies on an already reduced diet.

If you are noticing more hunger at a stable dose, the relationship between semaglutide and appetite is worth understanding in detail before drawing conclusions about whether your treatment is working.

Dose transitions and why appetite often shifts around them

The standard Wegovy escalation moves through 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg, with roughly four weeks at each level before the prescriber moves the dose up. Each increase tends to renew appetite suppression, which is part of why the titration schedule is structured as it is. Between increases, as the body equilibrates to the current dose, some of that suppression softens.

The practical implication is timing. If your appetite returns notably in weeks three or four of a given dose, that pattern is consistent with normal pharmacodynamics. It is worth noting in your clinical record because it is useful context for your prescriber when deciding whether a dose increase is appropriate or whether other factors are at play.

The NHS semaglutide medicines page provides a clear overview of how the schedule works and what to expect at each stage. Any decision about adjusting your dose or timing belongs with your prescriber, not the information on a label. Missed doses and timing changes should always be discussed with the clinician who issued your prescription.

Some people find their appetite is better managed when they look closely at what they are eating on Wegovy, not just how much. Protein adequacy and fibre intake both influence satiety independently of the medicine.

When appetite returns after stopping Wegovy, a different question entirely

It is worth distinguishing two separate situations. Appetite shifting during treatment, covered above, is different from appetite rebounding after treatment ends. Post-treatment hunger return is well-documented: semaglutide's effects on appetite signalling reverse when the drug clears the body, which typically takes several weeks given its long half-life. Trial extension and follow-up data consistently show that weight regain accelerates once semaglutide is discontinued, driven substantially by the return of pre-treatment appetite levels and reduced energy expenditure.

If you are considering stopping, have stopped, or are thinking through what happens next, our page on appetite returning after stopping semaglutide covers that evidence specifically. The considerations are different and deserve their own space.

For those currently on treatment who have noticed a change, the distinction matters: in-treatment fluctuation is usually manageable within the current plan, whereas post-treatment rebound requires a different clinical strategy. The Wegovy overview brings together the broader picture of how treatment works and what ongoing clinical support looks like.

Practical steps worth discussing with your prescriber

If appetite has returned noticeably and feels harder to manage, a few things are worth raising at your next clinical review. First, whether the timing aligns with your dose cycle, a consistent pattern in weeks three and four suggests the dose may be appropriate to review. Second, whether anything external has changed: sleep quality, stress levels and alcohol use all influence appetite signalling, and a period of disrupted sleep can meaningfully increase hunger regardless of medication.

Third, meal composition. This is where clinical guidance and practical habit meet. Diets high in ultra-processed foods tend to override satiety signals even on semaglutide; adequate protein at each meal supports the fullness effect the medicine provides. Guidance on building meals that work alongside treatment is available through our page on low appetite on Wegovy, which covers the other end of the spectrum but includes the same nutritional principles.

Appetite management on a GLP-1 medicine is not a set-and-forget situation. It needs periodic reassessment, and that reassessment is part of what a prescriber is there for. At nume, a real clinician reviews your progress before every repeat order, not a form, not an algorithm. If appetite changes are affecting your treatment experience, speak to our prescribers and get a clear clinical view of what is happening and what the options are.

Questions about the cost of ongoing treatment are also reasonable. A straightforward comparison of what different providers include in their pricing is on the Wegovy price comparison page.